GlassScriptPhysician profile
Lawrence S Carter
NPI 1003811480
$4,820.96
in general payments reported to CMS, 2019-2025
42 companies · $541 in 2025
The $541 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $296 · 2021: $695 · 2022: $721 · 2023: $720 · 2024: $771 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,881.58 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $635.72 | 2021-2025 | |
| Abbvie INC. | $370.11 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $361.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Biogen, INC. | $313.97 | 2019-2025 | Tysabri |
| Allergan, INC. | $305.14 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $288.12 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $250.06 | 2019-2022 | |
| Novo Nordisk INC | $245.83 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $228.90 | 2020-2025 | Jardiance, Zepbound, Emgality |
| Janssen Pharmaceuticals, INC | $169.61 | 2022 | |
| Pfizer INC. | $168.16 | 2019-2024 | |
| Arbor Pharmaceuticals, INC. | $127.91 | 2019-2020 | |
| Abiomed | $123.65 | 2024 | Impella |
| Biohaven Pharmaceuticals, INC. | $118.48 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $105.20 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.